ctDNA Promising Biomarker in Ribociclib, Letrozole-Treated HR+/HER2- Advanced Breast Cancer

Liquid biopsies were used to determine whether ctDNA analysis was predictive of disease progression in women with HR+/HER2- breast cancer.